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Abstract
Background: Nrf1 (nuclear factor-erythroid 2 p45 subunit-related factor 1) is a transcription factor mediating cellular
responses to xenobiotic and pro-oxidant stress. Nrf1 regulates the transcription of many stress-related genes through the
electrophile response elements (EpREs) located in their promoter regions. Despite its potential importance in human health,
the mechanisms controlling Nrf1 have not been addressed fully.
Principal Findings: We found that proteasomal inhibitors MG-132 and clasto-lactacystin-b-lactone stabilized the protein
expression of full-length Nrf1 in both COS7 and WFF2002 cells. Concomitantly, proteasomal inhibition decreased the
expression of a smaller, N-terminal Nrf1 fragment, with an approximate molecular weight of 23 kDa. The EpRE-luciferase
reporter assays revealed that proteasomal inhibition markedly inhibited the Nrf1 transactivational activity. These results
support earlier hypotheses that the 26 S proteasome processes Nrf1 into its active form by removing its inhibitory N-
terminal domain anchoring Nrf1 to the endoplasmic reticulum. Immunoprecipitation demonstrated that Nrf1 is
ubiquitinated and that proteasomal inhibition increased the degree of Nrf1 ubiquitination. Furthermore, Nrf1 protein
had a half-life of approximately 5 hours in COS7 cells. In contrast, hypoxia (1% O2) significantly increased the luciferase
reporter activity of exogenous Nrf1 protein, while decreasing the protein expression of p65, a shorter form of Nrf1, known to
act as a repressor of EpRE-controlled gene expression. Finally, the protein phosphatase inhibitor okadaic acid activated Nrf1
reporter activity, while the latter was repressed by the PKC inhibitor staurosporine.
Conclusions: Collectively, our data suggests that Nrf1 is controlled by several post-translational mechanisms, including
ubiquitination, proteolytic processing and proteasomal-mediated degradation as well as by its phosphorylation status.
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Introduction
Nrf1 (nuclear factor-erythroid 2 p45 subunit-related factor 1)
belongs to the cap-n-collar (CNC) subfamily of basic leucine zipper
(bZIP) transcriptional factors including Nrf1, Nrf2, Nrf3,
p45NFE2 (p45NFE2, nuclear factor-erythroid 2 p45 subunit),
Bach1 (BTB (Broad-complex, Tramtrack, and Bric-a-brac) and
CNC (cap’n’collar) homology 1, basic leucine zipper transcription
factor) and Bach2. These factors must bind to small Maf or c-Jun
proteins prior to DNA binding [1]. The sequence required for
DNA-binding of CNC-bZIP (cap’n’collar/basic leucine zipper)
factors is known as the electrophile response element (EpRE; also
referred to as the antioxidant response element (ARE)) with a
consensus sequence of 59-TGAnnnnGC-39 [2]. Antioxidant and
cytoprotective genes, regulated transcriptionally through their
EpREs, include NAD(P)H:quinone oxidoreductase 1, the gluta-
thione-S-transferases, ferritin, heme oxygenase-1, catalase and
superoxide dismutase [3]. Since Nrf1 controls phase 2 detoxifica-
tion enzymes that aid in metabolism and removal of potential
carcinogens, and due to the fact that potent EpRE-inducers such
as sulforaphane are known chemopreventive agents, understand-
ing the mechanisms of Nrf1 regulation may aid in the
development of cancer therapeutics. Furthermore, due to the
cytoprotective nature of phase 2 enzymes against oxidative stress-
induced neurodegeneration [4], manipulation of the upstream
factors controlling these enzymes (e.g., Nrf1 and Nrf2) could be
useful in the search of therapeutic targets against chronic
neurodegenerative diseases [4].
Currently, the mechanisms controlling Nrf2 activity have been
studied in great detail, while studies examining Nrf1 regulation are
lacking. However, it has been shown that Nrf1 may play as an
important role in human pathologies as Nrf2 [5]. Nrf2 was initially
thought to be kept in the cytosol under homeostatic conditions by
interaction with Keap1 (Kelch-like ECH (erythroid cell-derived
protein with cap’n’collar homology)-associated protein 1) [6],
which favors its rapid ubiquitination and degradation by the
proteasome [7]. When the cell encounters oxidative stress, the
Keap1-mediated proteasomal degradation of Nrf2 is compromised
[8], allowing Nrf2 to dissociate from Keap1 and translocate to the
nucleus to activate EpRE-driven gene expression. Further analysis
has shown that homeostatic Keap1-Nrf2 interactions are not
permanent and take place in the nucleus via transient shuttling of
Keap1 into that compartment [9]. In contrast, Nrf1 is not
regulated by Keap1 [10]. Instead, the activity of Nrf1 appears to
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29167be negatively controlled by its N-terminal domain (NTD), which
directs Nrf1 to the endoplasmic reticulum (ER) [10–12]. Nrf1, but
not Nrf2 or Nrf3, is essential for embryonic development; nrf1
2/2
mice die at mid-late gestation, presumably due to anemia-induced
hypoxia [13]. Recently a unique set of genes, controlled by Nrf1,
have been identified and contain metallothioneins-1 and -2 (MT1
and MT2 respectively) [14].
Nrf1 localizes primarily to the ER (see Figure 1) as well as the
nuclear envelope membrane [11]. The ER membrane-resident
form of Nrf1 represents a low activity, glycosylated protein with an
apparent molecular weight of 120 kDa (p120), while the nuclear
form (p95) is an active, non-glycosylated (or deglycosylated)
protein [15, see also Figure 1]. The ER location of Nrf1 is
thought to be suitable for the maintenance of the ER redox
homeostasis [11], perhaps by affecting the ER membrane lipid
organization via its amphipathic, transmembrane a-helices and
participating in membrane-dependent biological events [16]. It
has also been proposed that the localization of Nrf1 within the ER
determines the activity of this CNC factor and that the ER redox
status and Nrf1 glycosylation status could cause Nrf1 to relocate
from the ER to the nucleus [11]. As ER-resident Nrf1 is entirely
glycosylated and nuclear-localized Nrf1 is entirely non- or
deglycosylated, it has been hypothesized that Nrf1 deglycosylation
could represent the main mechanism of its regulation [11]. Also, it
has been hypothesized that Nrf1 is activated by the proteasomal
cleavage of its N-terminus to remove its inhibitory NTD,
producing smaller, more active forms of Nrf1 [17]. In addition,
there is a p65 form of Nrf1, presumably arising from Nrf1
translation initiating at an internal start codon [18] although the
possibility of the p65 arising as a result of a proteolytic cleavage
can not be ruled out [15]. p65 has been shown to act as a
dominant negative inhibitor of Nrf2-mediated, EpRE-driven
luciferase activity [19]. Apart from antagonistic competition of
Nrf1 p65 (and, potentially, full-length Nrf1) with Nrf2 for the
EpRE binding site, the nrf2 promoter contains two EpRE
sequences [20], which may provide Nrf1 with yet another means
of regulating Nrf2 expression.
Recent studies have established Nrf1 as a pivotal transcriptional
regulator of the genes of subunits of the proteasome. Thus, Nrf1
activates proteasome gene expression upon proteasome inhibition
treatment in human Ea.hy926 cells [21] and mouse embryonic
fibroblasts [22] to compensate for the loss of proteasome activity.
Similarly, Nrf1 conditional knock-out studies in mice brain lead to
proteasomal impairment, further confirming the importance of
Figure 1. The structural domains of Nrf1, its function and predicted topology within the ER membrane. The structural domains in
human Nrf1 (hNrf1) amino acid sequence were identified using a multiple amino acid alignment with mouse Nrf1 (mNrf1) sequence and domain
designations as reported in [10]. The hNrf1 domains are: NTD, N-terminal domain (amino acids 1–124); AD1, acidic domain 1 (amino acids 125–324);
NST (Asn/Ser/Thr-rich region) (amino acids 325–432); AD2, acidic domain 2 (amino acids 433–482); SR (Ser repeat) domain (amino acids 483–519);
Neh6L (Neh (Nrf2-ECH homology) 6-like) domain (amino acids 520–611); CNC, cap’n’collar domain (amino acids 612–655); bZIP, basic Leu zipper
domain (amino acids 656–717); CTD, C-terminal domain (amino acids 718–772). The topology of mNrf1 was predicted by Zhang and others [11]. TM1,
TMi and TMc are putatitve trans-ER membrane regions. Nrf1 is synthesized as an ER-targeted protein and, once inserted into the ER membrane via
TM1, TMi and TMc, is glycosylated in the ER lumen; the Nrf1 glycoprotein is referred to as p120. Following the translocation of the luminal part of the
p120 into the nucleoplasm, it is deglycosylated to become active p95 Nrf1, heterodimerizes with small Maf or c-Jun proteins and binds to the EpRE to
activate the expression of genes involved the antioxidant defense and phase II detoxification metabolism. Internal translation or proteolysis gives rise
to p65 Nrf1, dominant negative repressor of the EpRE-driven gene expression. Glycosylation sites are represented by ‘‘Y’’. Drawing of the domains
and specific regions of Nrf1 were performed to scale.
doi:10.1371/journal.pone.0029167.g001
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expression [23]. Although previous work provided solid evidence
for the link between Nrf1 and proteasome, the relationship
between different forms of Nrf1 has been essentially absent or
received very little attention in the previous studies. Here, we
present the evidence supporting two levels of proteasomal
regulation of Nrf1 function. In addition, we describe the hypoxic
inducibility of Nrf1 and potential regulation of Nrf1 function by
phosphorylation. The present study shows that exogenous Nrf1
activity correlates inversely with the abundance of the p65 form of
Nrf1, a known inhibitor of the EpRE-mediated gene expression.
The derepression of Nrf1 activity by the removal of the inhibitory
p65 Nrf1 form may be one of several determinants of Nrf1
activation under hypoxia.
Results
Proteasomal inhibition stabilizes p120 and ubiquitinated
Nrf1
Closely-related CNC-bZIP factors Nrf2 and Nrf3 have been
shown to be controlled through keeping their intracellular levels
low under homeostatic conditions through the proteasomal
degradation [24,25]. To test if Nrf1 is also regulated via
proteasomal degradation, we analyzed its protein expression in
the presence of proteasomal inhibitors clasto-lactacystin-b-lactone
(lactacystin) and MG-132. Proteasomal inhibition with both
inhibitors greatly enhanced the expression of inactive, ER-bound
glycosylated form of Nrf1, p120 (Figures 2A and B). Interestingly,
while the density of the p120 band increased significantly (about
140% compared to controls) during MG-132 treatment, the
intensity of the band, corresponding to the active, nuclear
glycosylated/deglycosylated p95 Nrf1 form decreased about 20%
compared to DMSO (Figures 2B and C). This could imply that
higher levels of p120 could arise, at least in part, due to increased
glycosylation of p95, in response to proteasomal inhibition.
Noteworthy is that the decrease in the level of p95 observed in
Figure 2B is subtle (20% only) and, while being statistically
significant, may not be biologically relevant. In addition, no
alteration of the p95 expression was not seen for lactacystin as the
p95 expression during this treatment was unaltered, indicating that
the stabilization of p120 may proceed independently of p95 Nrf1.
When COS7 cells were treated with an oxidative stressor 2,29-
azobis(2-amidinopropane) dihydrochloride (AAPH), we observed
the accumulation of p95 form without any apparent effect on the
p120 form of Nrf1 (see Figure S1). This result suggests that there
may be some time lag between the accumulation of p120 and p95
forms of Nrf1, given the time required for the deglycosylation
conversion of p120 to p95 Nrf1.
Nrf1 contains a PEST motif and is rapidly degraded
Nrf2 and Nrf3 have half-lives (t1/2) of approximately 15 and
30 minutes, respectively [24,25] and contain two strong putative
PEST sequences [25,26]. PEST sequences are rich in Pro, Glu,
Thr and Ser and are found frequently in rapidly degraded
proteins; the Ser and Thr residues are potential phosphorylation
sites [27]. We used the PESTfind analysis tool (http://www.at.
embnet.org/toolbox/pestfind/) to search for any putative PEST
sequence on Nrf1 and found that Nrf1 has a strong PEST motif
(amino acids 141–169) in its NTD (see Figure 1 for Nrf1 domains).
To test whether Nrf1 is indeed subject to rapid degradation, as
suggested by the presence of strong PEST motif, we applied
cycloheximide (CHX) and analyzed Nrf1 protein degradation by
immunoblotting when protein synthesis was inhibited (Figure 3A).
A plot of band density versus time (Figure 3B) showed that the t1/2
of p95 and p120 is approximately 5 hours (data not shown).
Compared to transcription factors Nrf2 and Nrf3, Nrf1 is more
than 5 to 10 times more stable, but the Nrf proteins are less stable
than other proteins that have t1/2 between 16 (lysozyme) and 210
(phosphoglycerate kinase) hours [28]. Nrf1 can therefore be
regarded as a relatively short-lived protein; however, relatively
long half-life, compared to that of other transcription factors,
suggests that Nrf1 activity may be regulated by other mechanisms,
such as post-translational modifications. Next, we found that anti-
Nrf1 antibody was able capture significantly higher levels of
ubiquitinated Nrf1 protein, in co-immunoprecipitation experi-
ments, as revealed by immunoblotting with anti-ubiquitin
antibody (Figure 3C). Thus, Nrf1 is precisely controlled by
keeping its levels low through its continuous ubiquitination and
degradation by the proteasome. Given its relatively long half-life,
compared to Nrf2 and Nrf3, Nrf1 may have additional
modifications that allow for ubiquitination, similar to the large
subunit of RNA polymerase II (RPB1), which requires phosphor-
ylation prior to ubiquitination in order to be degraded by the
proteasome [29]. Ubiquitination of the target protein would be
dependent upon conditions required for the primary post-
translational modification to occur. Thus turnover of Nrf1 may
be higher under conditions that favour other post-translational
modifications.
In addition to ubiquitination, we noticed the disappearance of a
high molecular weight form of Nrf1 with an approximate
molecular weight of 250 kDa (p250) as a result of CHX treatment,
oxidative stress (AAPH or tert-butylhydroquinone (tBHQ)) and
hypoxia treatments (see Figure S2). Furthermore, we observed a
similar decrease in the p250 from content in aged mice tissues
(data not shown). The identity of this stress-modulated band merits
further investigations and could represent post-translational
modification of Nrf1 (e.g., ubiquitination), Nrf1 homodimer, ER
membrane-bound Nrf1 or Nrf1 tightly bound to an unknown
protein.
Comparison of Nrf1 protein expression under
proteasomal inhibition and hypoxia
With the observation that MG-132 and lactacystin stabilized
p120, we wanted to determine if the protein expression of Nrf1 is
also affected by hypoxia. To this end, we subjected COS7 and
WFF2002 cells to hypoxic conditions (1% O2). Hypoxia is known
to induce the expression of genes involved in iron metabolism,
many of which are transcriptionally regulated via the CNC-bZIP
factors to which Nrf1 belongs [30]. Similarly, hypoxia activates the
expression of MT1 and MT2 [31]; these genes contain the EpRE
sequence and are known targets of Nrf1, but not Nrf2 [14].
Intracellularly, hypoxia treatment has many similarities with
proteasomal inhibition; for instance, hypoxia-inducible factor
alpha subunits (HIFas) are stabilized when the proteasome is
inhibited, which leads to HIFa-mediated activation of hypoxia-
inducible gene expression. In addition, multiple studies have
reported an increased rate of reactive oxygen species (ROS)
production under hypoxia [32] and ROS are known activators of
the EpRE-Nrf1 pathway. Given that hypoxia results in the
generation of ROS, we wanted to study the effects of hypoxia on
Nrf1 function in order to elucidate the mechanisms of Nrf1
regulation in greater detail.
Unlike MG-132 treatment, no stabilization of p120 form was
observed in hypoxic treatments for both cell lines (Figures 4A and
B), suggesting that the effect of combining these two treatments is
not different from applying each treatment individually. Since the
accumulation of p120 form was also noticeable in WFF2002 cells
(Figure 4A), the mechanism of Nrf1 control through proteasomal
Nrf1 Regulation by Hypoxia and Proteasome
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corresponding to p65 Nrf1, a dominant negative inhibitor of
EpRE-driven gene expression [19], was markedly increased after
6 hours of MG-132 treatment in WFF2002 cells (Figure 4A) and
in both MG-132- and hypoxia-treated COS7 cells (Figure 4B).
Very little is currently known about p65 and its role in EpRE-
mediated gene expression, apart from its negative effect on the
EpRE pathway and cell type-specific accumulation of p65 might
provide some hints towards its function and regulation. We
observed no changes at the mRNA levels for all four conditions
tested (data not shown), supporting the involvement of post-
translational modifications in Nrf1 regulation by the proteasome
and hypoxia.
Interestingly, in both cell lines, the intensity of the band
migrating as a 23 kDa protein (‘‘p23’’ Nrf1) was diminished during
proteasomal inhibition (see Figures 4A and B). Since our anti-Nrf1
antibody recognizes the N-terminal fragment of Nrf1 (amino acids
191–475), and p23 is always highly expressed, this suggests that
this is a product of N-terminal cleavage, in addition to the
ubiquitin-dependent proteasomal degradation discussed above.
p23 likely represents either protease- and/or a stable, proteasome-
generated N-terminal fragment of Nrf1. This is in line with the
previous studies, suggesting that p120 Nrf1 must be processed into
smaller forms in order to remove the inhibitory NTD and allow
the protein to act as a transcription factor (see [17] and references
therein). The N-terminal cleavage of Nrf1 might be an important
way of regulating this factor as that would allow it to escape ER
and to translocate to the nucleus, where it could activate the
expression of the EpRE-controlled genes. Other ER-bound
transcriptional factors are similarly regulated, such as the sterol-
regulatory-element-binding proteins SREBP1 and SREBP2, as
well as activating transcription factor 6 (ATF6; via intramembrane
proteolysis), and this regulation has been well-characterized (see
[12] and references therein). Previous studies [15,16] failed to map
any proteolytic cleavage site within the first 170 amino acids at the
N-terminus; however, the studies were performed at normal
Figure 2. Nrf1 is stabilized by proteasomal inhibition in COS7 cells. COS7 cells were treated with 5 mM lactacystin (A)o r1 0mM MG-132 (B)
for six hours and Western blots were performed with anti-Nrf1 antibody as described in the Materials and Methods section. DMSO (the solvent used
for lactacystin and MG-132) was used for controls. (C) Shown is the densitometry analysis of the blots using the results of four independent
experiments (means 6 SEM). Asterisks (*) indicate significant difference (p,0.05) compared to control.
doi:10.1371/journal.pone.0029167.g002
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intramembrane proteolysis under stimulated conditions cannot be
ruled out [16]. In contrast, a more recent study [21] provided
some, albeit indirect, support for the intramembrane proteolysis of
Nrf1 prior to its translocation to the nucleus from the ER.
MG-132 and hypoxia enhances protein binding to EpRE
Once we showed that proteasomal inhibition stabilizes Nrf1, we
investigated whether MG-132 and/or hypoxia have any effects on
Nrf1 DNA-binding to the EpRE. Using electrophoretic mobility
shift assays (EMSAs), we observed the appearance of MG-132-
and hypoxia-inducible bands (Figure 5A), whose density was
significantly different from controls (Figure 5B). These results are
consistent with the previously reported study of Waleh and co-
workers [33], showing hypoxia-inducible DNA-binding to EpREs
in human HepG2 and mouse Hepa cells.
To identify the proteins responsible for the hypoxia- and MG-
132-inducible EpRE-binding, we used an immunodepletion
approach [34]. In this method, an antibody raised against a
DNA-binding protein diminishes the intensity of an EMSA band if
the DNA-binding protein is, indeed, bound to the target DNA
sequence under investigation [34]. Apart from Nrf1, the obvious
candidate factors that could be involved in the MG-132- and
hypoxia-inducible EpRE complex formation could be Nrf2 as it is
stabilized by proteasomal inhibition and Bach1, whose activation
by hypoxia has been previously described [35]. As can be seen
from Figures 5C and D, anti-Nrf1 antibody significantly
diminished the intensity of the inducible band compared to the
actin (non-specific) antibody, used as a negative control
(Figure 5D). This suggests potential involvement of Nrf1 in the
hypoxia- and MG-132-inducible binding to an EpRE probe.
However, since enhanced EpRE binding could result in either
activation or repression of the EpRE target genes, depending on
the nature of the binding factor involved (activator or repressor),
we used a luciferase reporter assay, in combination with Nrf1
overexpression, to gain a better understanding of the Nrf1
transactivation function in response to hypoxia and proteasomal
inhibition treatments.
Hypoxia activates while proteasomal inhibition inhibits
exogenous Nrf1 activity
Next, we tested if proteasomal inhibition and hypoxia have any
effect on the transactivation activity of Nrf1. To this end, we used
a luciferase reporter vector under the control of three EpREs from
chicken b-globin enhancer (3xEpRE-luciferase [21]). Transient co-
transfection of 3xEpRE-luciferase with Nrf1-FLAG in COS7 cells
showed that 24-hour hypoxia treatments greatly increased the
activity of Nrf1-FLAG (Figure 6A). Furthermore, hypoxic
activation of Nrf1 is probably not cell type-specific as the same
result was seen in HEK293A cells (Figure 6A). In addition to low
oxygen, Nrf1-FLAG activation is achievable by hypoxia mimetics
cobalt chloride and dimethyloxalylglycine (DMOG, Figure 6C). In
contrast, MG-132 markedly decreased the activity of Nrf1-FLAG
while hypoxia had no effect on the Nrf1 activity during six-hour
treatments (Figure 6B). Again, the action of MG-132 on
exogenous Nrf1 activity can be understood in light of the current
hypothesis that the processing of Nrf1 by the 26S proteasome
could remove its inhibitory NTD (see Figure 1 for Nrf1 domains),
targeting Nrf1 to the ER. Blocking Nrf1 processing into p23 and
other active forms of Nrf1 (such as p95) by proteasome inhibition
Figure 3. Nrf1 is a short-lived protein and undergoes ubiquitination and proteasomal degradation. (A) COS7 cells were treated with
12 mM MG-132 for five hours, the medium was replaced by fresh medium with 100 mg/mL CHX and the cells were harvested at different time intervals
(0–8 hours) and subjected to immunoblotting for Nrf1 p95. (B) The graphical determination of Nrf1 p95 half-life (t 1/2) using at least three
independent experiments is shown. (C) Immunoprecipitation was performed as described above in the Materials and Methods section on the lysates
of COS7 cells pre-treated with 10 mM MG-132 or DMSO for six hours and the results of two independent experiments are shown.
doi:10.1371/journal.pone.0029167.g003
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observed repression of the Nrf1 activity by MG-132 treatment
(Figure 6B). Therefore, proteasomal processing seems to be a
prerequisite for Nrf1 activation and function.
Potential effect of p65 on the hypoxia-inducibility of Nrf1
Thep65formofNrf1 isthoughttobe produced byeitherinternal
proteolysis [15] or as a result of translation initiation from an
alternative Met codon [18]. The p65 form of Nrf1 acts as a
dominant negative inhibitor of the EpRE-driven gene expression
[19] as it contains a DNA-binding domain, but lacks a transactiva-
tion domain, such that p65 Nrf1 competes with Nrf2 for the EpRE
binding site. As seen in Figures 6D and E, the expression of the p65
form of Nrf1 markedly decreased during hypoxia treatment in both
COS7 and HEK293A cell lines, while no other common change
was noticeable during hypoxia. Our data presented here is in
agreement with the model in which the EpRE-mediated gene
expression is activated as a result of down-regulation of the
inhibitory p65 form of Nrf1. The two internal Met residues that are
thought to give rise to p65 are M321 and M326 [18] which contain
consensus Kozak sequences, not presentin the M1 codon. Mutating
M321 and M326 to M321L and M326L, respectively, resulted in
significant loss of basal Nrf1-FLAG activity and hypoxia-inducibil-
ity; however, unexpectedly, mutants were not expressed at
detectable levels (data not shown). This may be due to increased
instability or aggregation of mutant forms of Nrf1 (that are
potentially cytotoxic) compared to wildtype Nrf1.
Nrf1 is activated by phosphorylation
Our computational analyses predicted a high probability of
Nrf1 phosphorylation by cdc2 and protein kinase C (PKC)
members, especially at the Ser-rich region (NST), facing the ER
lumen. Zhang and others [11] provided some evidence that
phosphorylation of Nrf1 at its NTD (which contains two potential
Tyr phosphorylation motifs, amino acids 62–70 in human Nrf1),
may weaken the Nrf1 association with the ER, stimulating the
Nrf1 trafficking to the nucleus. Given that phosphorylation by
atypical PKC is known to activate Nrf2 [36], we thought that Nrf1
could also be a subject to this modification. To test that, we
performed luciferase assays on the COS7 cells co-transfected with
Nrf1-FLAG and 3xEpRE-luciferase and subjected to protein
phosphatase inhibitor okadaic acid (OA) [24] or pan-PKC
inhibitor staurosporine [37]. Figure 7 illustrates that OA activated
Nrf1, while staurosporine repressed Nrf1 activity, suggesting that
Nrf1 phosphorylation plays a role in Nrf1 transactivation. Notably,
the OA treatment resulted in about 2-fold increase of the empty
vector-mediated EpRE-luciferase activation, changing the EpRE-
driven luciferase activity from 1.0 to 2.0-fold with respect to
Figure 4. Comparison of the Nrf1 expression under hypoxia and proteasomal inhibition. WFF2002 (A) and COS7 (B) cells were treated
with normoxia (21% O2), hypoxia (1% O2), 10 mM MG-132 or hypoxia and MG-132 combination for six hours and subjected to Western blotting. The
band density was normalized with respect to b-tubulin (b-tub) or ponceau S red staining (p. stain) and is presented as means 6 SEM of at least three
independent experiments for WFF2002 (C) and COS7 (D) cells. Asterisks (*) indicate significant difference (p,0.05) compared to control.
doi:10.1371/journal.pone.0029167.g004
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the ‘‘noise’’ signal due to other transcriptional factors, such as
Nrf2, being activated through phosphorylation. On the other
hand, treatment with OA changed the EpRE-luciferase reporter
activity due to Nrf1-FLAG from 8.15 to 10.3-fold with respect to
the control. Therefore, the net increase in Nrf1-FLAG activity was
2.15-fold compared to 1-fold increase due to ‘‘noise’’. These
results, as well as a similar study on the effect of OA on Nrf2
(where an approximate 0.5-fold increase in the Nrf2 activity due to
OA treatment above background was interpreted as a stimulatory
effect of OA on Nrf2 activity (see Figure 6 in [24])), suggests that
Nrf1 positively responds to phosphorylation stimulus. Decreased
transactivation activity of Nrf1, as a result of staurosporine
treatment, strengthens the claim that the phosphorylation status of
Nrf1 is important for Nrf1 activity. It is possible that some
upstream factors in the signaling cascade that control Nrf1
function responds to phosphorylation/dephosphorylation rather
than Nrf1 itself and further studies are required to confirm the
target of phosphorylation in the Nrf1 pathway.
Discussion
The two levels of the proteasomal control of Nrf1
The levels of key inducible transcription factors are normally
kept low under homeostatic conditions through their ubiquitina-
tion and continuous degradation to avoid aberrant gene
expression. This is the case for transcription factors such as HIFa
and the CNC-bZip factors Nrf2 and Nrf3. As expected, we found
that Nrf1 was also negatively regulated by the proteasome, being
subject to ubiquitination and proteasomal degradation in agree-
ment with Zhang and co-workers, who suggested that Nrf1
abundance may be controlled by the proteasome [11]. We
observed high expression of the p23 fragment of Nrf1 under
untreated conditions, which diminished following MG-132
treatment. Since p23 would be expected to contain about 210
amino acids, and the recognition region of our antibody is between
amino acids 191–475, we believe that p23 represents an N-
terminal fragment of the Nrf1 cleaved twice in the amino acids
191–475 region with the distance between the two cleavage sites
being approximately 210 amino acids. Further support of this
hypothesis has been shown in previous experiments, where Site-1
or Site-2 protease cleavage sites within the first 170 amino acids of
Nrf1 could not be identified [15,16]. Thus, our results support the
hypothesis of Zhang and co-workers [15] that Nrf1 is proteolyt-
ically cleaved at regions other than NTD. Cleavage by Site-1 and
Site-2 intramembrane proteases is a well-known mechanism,
responsible for the release of ER-bound transcriptional factors, but
the possibility that Nrf1 is cleaved at AD1, NST and AD2 domains
merits further investigation. This possibility is also supported by
Steffen and co-workers [21], who noticed that the molecular
Figure 5. Hypoxia and proteasomal inhibition increase protein binding to the EpRE. Biotin-labelled EpRE probe from gclm promoter was
applied to 20 mg of total COS7 cell lysate protein in an EMSA format as described in the Materials and Methods section. (A) Depicts the appearance of
the hypoxia- and MG-132-inducible band. C, PI, H and PI+H designate control (DMSO), proteasomal inhibition (MG-132), hypoxia (1% O2 and DMSO)
and the combination of hypoxia and MG-132 treatments, respectively. I=induced band, F=free probe. (C) The identity of the EpRE-bound complex
was probed using antibodies against the proteins indicated in the immunodepletion format. I=induced band, F=free probe, S=supershift. (B) and
(D) are graphical representations of the outcomes of the experiments presented in (A) and (C), respectively, as the means of band densitometry 6
SEM for at least three independent experiments. Asterisks (*) indicate significant difference (p,0.05) compared to control.
doi:10.1371/journal.pone.0029167.g005
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nuclear form of Nrf1 and concluded that intramembrane
proteolysis is a feasible mechanism for Nrf1 release to the nucleus
from the ER.
The second or ‘‘positive’’ level of Nrf1 regulation by the
proteasome, in addition to ubiquitin-mediated proteasomal
degradation, appears to be proteolytic processing. In accord with
the current hypothesis of the Nrf1 regulation by removal of the
NTD domain from full-length Nrf1 [17], proteolytic cleavage of
Nrf1 allows it to bypass insertion into the ER and travel to the
nucleus. This hypothesis was supported by the fact that
proteasomal inhibition with MG-132 not only stabilized p120
Nrf1 and decreased p23 levels, but also repressed Nrf1 activity. A
very similar mode of activation, through the processing of p105 to
the DNA-binding p50 form of NF-kB by the 26 S proteasome, has
been described [38,39]. A recent study has demonstrated the
involvement of Nrf1 in the ‘‘bounce-back’’ response, an elevated
proteasomal subunit synthesis which is observed upon proteasome
inhibition [22]. According to the study, Nrf1 directly activates the
proteasome recovery pathway upon proteasome inhibition. For
that to happen, Nrf1 itself must be activated by 1 mM MG-132
treatment, which was shown by the investigators [22]. This is in
contrast to our results, as well as the results of others (see Figure 2
of ref. [11]), demonstrating that MG-132 and another proteasome
inhibitor, ALLN, applied at 10 or 13 mM concentrations
respectively, represses exogenous Nrf1 activity. While both 1 and
10–13 mM concentrations of the proteasome inhibitors were able
to stabilize p120 Nrf1, abolishing the proteasomal degradation of
Nrf1 completely, it is conceivable that higher concentrations of
proteasomal inhibitors are required for the inhibition of the Nrf1
partial processing/activation by the proteasome (which is known
to possess several catalytic activities). Thus at low concentrations of
proteasome inhibitor, degradation of p120 Nrf1 is inhibited, but
not its processing (which activates Nrf1). At high concentrations of
proteasome inhibitor, both p120 Nrf1 degradation and processing
is inhibited, inhibiting Nrf1 function despite the fact that more Nrf
is present. Another possible explanation for this discrepancy is the
fact that reporter plasmids with EpREs from different genes were
used in previous and our studies and while one set of EpRE-
controlled genes can be turned on by a given conditions, other
EpRE-driven genes can be turned off due to the complex interplay
between co-activator and co-repressor proteins [40].
Figure 6. Hypoxia and hypoxic mimetics activate Nrf1, while MG-132 inhibits its transactivation activity. COS7 and HEK293A cells were
co-transfected with 36EpRE-luc, b-galactosidase and Nrf1-FLAG plasmids, treated with hypoxia, 10 mM MG-132, 2.5 mM DMOG or 200 mM CoCl2 for
twenty-four ((A) and (C)) or six (B) hours as indicated and the luciferase activity in the lysates was measured. The pCR3.1 plasmid, lacking Nrf1, was
used as negative control and b-galactosidase activity was used as the transfection efficiency control. The means of at least three independent
experiments 6 SEM, normalized to the b-galactosidase activity and pCR3.1 are presented. Asterisks (*, **) indicate significant difference (p,0.05 or
p,0.001, respectively) compared to control. The lysates of hypoxia-treated (1% O2, 24 hours) COS7 (D) and HEK293A (E) and (F) cells were also
subjected to immunoblotting using anti-FLAG antibody. In (D) and (E), asterisks (*) denote the non-specific, cross-reacting bands. Representative
blots of three independent experiments are shown.
doi:10.1371/journal.pone.0029167.g006
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Our findings have emphasized the role of multiple forms of
Nrf1. Indeed, Nrf1 is known to exist in several forms, including
p120 (glycosylated Nrf1), p95 (non- or deglycosylated Nrf1),
inhibitory p65 form as well as 46 and 30 kDa forms [11]. In
addition to these, we report the existence of the p23 Nrf1 form,
that seems to be a fragment of proteasomal processing of the full-
length Nrf1 and another, high molecular weight p250 Nrf1 form,
which is destabilized by oxidative stressors, inhibition of protein
synthesis and hypoxia. Since the p250 form responds to multiple
stimuli (see Figure S2), its characterization will be useful in further
attempts to uncover the mechanisms responsible for Nrf1
activation. It is plausible that the p250 form of Nrf1 represents a
covalently linked protein-protein or protein-membrane interaction
with Nrf1. The other possibility is a currently uncharacterized
post-translationally modified form of Nrf1 such as ubiquitinated
Nrf1.
Hypoxic activation of Nrf1 is accompanied by p65 Nrf1
down-regulation
The major significance of our study is that it is the first one to
report the alternation in the p65 form expression of Nrf1 in
response to a physiologically-relevant condition, hypoxia. The
decreased presence of the p65 form of Nrf1, affected by hypoxia,
correlated with the activation of Nrf1 activity in accordance with
the current knowledge of the inhibitory function of p65 [19]. This
is also the first study to report Nrf1 activation by hypoxia. As it has
been speculated that the location of Nrf1 in the ER membrane is
suitable for the maintenance of the homeostatic redox status of the
ER [11], the finding that Nrf1 is a hypoxia-modulated factor is not
surprising, given that hypoxia is known to cause the ER stress due
to the accumulation of the unfolded proteins in the ER lumen
[41]. Among the genes controlled exclusively by Nrf1 (and not
Nrf2) are the metallothioneins (MT 1 and 2) [14]. It was found
that MT expression is hypoxia-inducible in PCa cells [31] and,
according to our study, we think that Nrf1 hypoxic inducibility
could be responsible for MT upregulation in response to hypoxia.
Nrf1 is remarkable as its full-length p95 form can act as an
activator of the EpRE-driven gene expression while its shorter
form, p65, acts as an apparent inhibitor of the EpRE pathway.
Using transient overexpression of Nrf1-FLAG, we noticed that the
levels of the p65 Nrf1 were significantly lowered by hypoxia
(Figures 6D and E), which correlated to the increased tranactiva-
tion activity of Nrf1-FLAG (Figure 6A), suggesting that the cells
possess the ability to control Nrf1 activity by removal of the
inhibitory p65 form. However, hypoxic mimetic DMOG was
capable of activating Nrf1-FLAG without any apparent effect on
the p65 expression (Figures 6C and F), but with pronounced
increase of the full-length Nrf1 (p120) expression. This is
reminiscent of the recently reported, arsenite-mediated induction
of Nrf1, which was characterized by the stabilization of the p120
form of Nrf1 during the treatment of keratinocytes with arsenite
[42]. The involvement of other mechanisms such as phosphory-
lation in the hypoxic inducibility of Nrf1 can further augment
activation of this CNC-bZIP factor.
Concluding comments
This study has opened up new avenues of research regarding
the regulation of Nrf1. What is currently unknown is the kinase
and the Nrf1 residue(s) involved in Nrf1 phosphorylation. Zhang
and co-workers [11] speculated that Nrf1 phosphorylation can
take place at Tyr65 and Tyr77, which could weaken Nrf1 affinity
for the ER membrane and stimulate its nuclear import. As well,
the proteolytic processing of Nrf1 requires further investigation to
identify the protease responsible for as well as the site of the
cleavage. Furthermore, it is currently unknown how phosphory-
lation and processing of Nrf are controlled and if the two processes
are interdependent. Given that the p250 form of Nrf1 responds to
various stimuli, it would be extremely informative to determine
whether this form represents a hyperglycosylated or otherwise
modified form of Nrf1, why this form is destabilized under
stimulated conditions and what is the significance of that. Our
current working model of Nrf1 regulation is summarized in
Figure 8. According to our model, Nrf1 is a subject to several
regulatory events, including: i) negative regulation by the
proteasome through ubiquitin-mediated degradation; ii) positive
regulation by the proteasome through proteolytic processing to
generate the p23 fragment; iii) phosphorylation and iv) derepres-
sion of its transactivation activity by the removal of the inhibitory
p65 Nrf1 form.
Materials and Methods
Cell Culture, Transfection and Chemicals
HEK293A, COS7 and WFF2002 cells were purchased from the
American Type Culture Collection (ATCC, Mannasas, VA).
Dubecco’s modified Eagle’s medium (DMEM), penicillin-strepto-
mycin-antimycotic (P/S/A), horse serum (HS), newborn calf
serum (NCS), foetal calf serum (FCS), Opti-MEM I Reduced-
Serum Medium and Lipofectamine 2000 were purchased from
Invitrogen (Carlesbad, CA). Restriction enzymes and buffers were
from New England BioLabs (Ipswich, MA). Okadaic acid,
staurosporine and luciferin were from BioShop Canada (Burling-
ton, ON). Complete protease inhibitor cocktail tablets and
chlorophenol red-b-D-galactopyranoside (CPRG) were from
Roche Diagnostics (Basel, Switzerland). The protein determina-
tion assay kit was from BioRad (Hercules, CA). Anti-human Nrf1
antibody (sc-28379) and protein A/G Sepharose beads were
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).
Proteasome inhibitors MG-132 and clasto-lactacystin-b-lactone
(lactacystin), dimethylsulfoxide (DMSO), phenylmethylsulfonyl
Figure 7. Phosphorylation activates Nrf1 transactivation activ-
ity. Luciferase assays were performed on the COS7 cell lysates, co-
transfected with 36EpRE-luciferase, and Nrf1-FLAG plasmids treated
with okadaic acid (OA) and staurosporine (SS), to inhibit protein
dephosphorylation and phosphorylation, respectively. DMSO or ethyl
acetate (EA) was used as vehicle (V) controls in and the concentration of
each compound used. The means of at least three independent
experiments 6 SEM are shown. Asterisks (*) indicate significant
difference (p,0.05).
doi:10.1371/journal.pone.0029167.g007
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azobis(2-amidinopropane) dihydrochloride (AAPH) and other
basic chemicals were from Sigma-Aldrich (St. Louis, MO).
Expression Constructs
A luciferase reporter plasmid containing three EpREs from
chicken b-globin enhancer (36EpRE-luciferase) was a kind gift
from Dr. Masayuki Yamamoto (Tohuku University) and has been
described elsewhere [43]. Human Nrf1 gene from mammalian
gene collection (accession number BC010623) was inserted into a
modified pCR3.1 mammalian expression vector using NdeI and
EcoRI and then introduced into CMV-5a-FLAG vector (Sigma-
Aldrich) using EcoRI and Kpn1 restriction enzymes to create N-
and C-terminally FLAG-tagged Nrf1, respectively.
Cell Culture, Transient Transfection and Luciferase
Reporter Assays
COS7 cells were grown in DMEM supplemented with 10%
NCS and 3% P/S/A (300 units/mL penicillin G, sodium salt,
300 mg/mL streptomycin sulfate and 0.75 mg/mL Fungizone H in
0.85% saline) in a humidified atmosphere with 5% CO2 at 37uC.
HEK293A and WFF2002 cells were grown under the same
conditions, but with different sera (10% HS and 10% FCS,
respectively). Trypan blue exclusion tests were performed to make
sure that the treatments of the cells described here, including
hypoxia and proteasomal inhibitor treatments, were not cytotoxic
(data not shown). Hypoxic conditions were achieved by setting O2
at 1%, CO2 at 5% and the balance N2 in triple-gas incubators
(Thermo Forma, Rockford, IL). Cells were seeded in 6-cm or 6-
well plates at a density of 140,000 cells/mL and approximately
24 hours later were transiently transfected with Lipofectamine
2000 as per the manufacturer’s protocol (upon becoming at least
70% confluent). For a 6-cm plate, 0.2 mgo fb-galactosidase, 8.0 mg
of 36EpRE-luciferase and 2.4 mg of Nrf1-FLAG, or pCR3.1
(empty vector) plasmid DNA, were used. Twenty-four or forty-two
hours later, cells were treated for 24 or 6 hours, respectively, and
harvested such that the total amount of time after transfection was
48 h. A firefly luciferase reporter gene assay was performed to
measure EpRE-driven transcriptional activity. Cells were lysed in
25 to 50 mL of lysis buffer (25 mM glycylglycine (pH 7.8), 1%
Triton X-100, 15 mM KH2PO4, 15 mM MgSO4, 4 mM EDTA,
1 mM DTT and a complete protease inhibitor cocktail tablet
(Roche)). Approximately 4 to 12 mL of supernatant was added to
76 mL of luciferase assay buffer (2 mM ATP in lysis buffer) and
luciferase activity was assayed on a FLUOstar OPTIMA (BMG
LABTECH, Offenburg, Germany) luminescence microplate
reader. The reaction was initiated by the injection of 50 mLo f
200 mM luciferin solution. Luciferase assay values were normal-
ized to b-galactosidase assay results (a measure of transfection
efficiency). For b-galactosidase assay, cell lysates were incubated in
85 mL of 0.2 mg/mL of CPRG in 60 mM Na2HPO4, (pH 8.0),
10 mM KCl, 1 mM MgCl2, and 1 mM DTT, for 5 to 10 minutes,
and monitored at 580 nm. Transfection experiments were
reproduced at least three times and are presented as means 6
SEM.
Western Blotting and Co-Immunoprecipitation (Co-IP)
Harvested cells were lysed in 50 to 100 mL of cell lysis buffer
(20 mM HEPES pH 7.9), 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA and 25% glycerol, 1 mM DTT and 0.5 mM
PMSF) and an equal amount of total protein (determined using
BioRad protein assay and diluted 1:1 with 26Laemmli loading
buffer) was loaded on a 12% SDS-PAGE, run at 120 V for 1.5 to
2 hours and transferred onto Immobilon PVDF membrane
Figure 8. The proposed working model for the Nrf1 regulation by the proteasome and O2. Nrf1 is controlled at the level of protein
degradation by ubiquitin (Ub)-mediated proteasomal destruction such that the half-life of Nrf1 is approximately five hours. In addition, Nrf1 is also a
subject of proteasome-mediated proteolysis during which its N-terminus containing the inhibitory NTD is cleaved to convert Nrf1 from inactive, ER-
bound p120 form to the nuclear, active p95 form. Nrf1 can be also activated through its phosphorylation. Hypoxia acts on p65 Nrf1 to diminish its
expression. This relieves the Nrf1 p65-mediated repression (by the removal of p65) on the p95 transactivation activity, which, in combination with
p95 activation by phosphorylation may greatly affect the expression of the Nrf1-EpRE target genes.
doi:10.1371/journal.pone.0029167.g008
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probed with 5% milk in Tris-Buffered Saline, Tween-20 (TBST)
for 1 hour. Western blot analysis for Nrf1 was performed using
mouse anti-human Nrf1 antibody (1:1,000 dilution), and horse-
radish peroxidase-labelled anti-mouse IgG secondary antibody
(1:2,000 dilution; DAKOCytomation, Mississauga, ON). FLAG-
tagged Nrf1 was visualized using horseradish peroxidase (HRP)-
conjugated mouse anti-FLAG M2 antibodies (1:4,000 dilution;
Sigma-Aldrich). As a loading control, membranes were probed
with mouse anti-human b-tubulin (1:4,000 dilution, Developmen-
tal Studies Hybridoma Bank, Iowa City, IA) or stained with
Ponceau S red. Blots were developed by enhanced chemilumi-
nescence substrate (Millipore, Bedford, MA) and Kodak X-Omat
blue film (Perkin-Elmer, Waltham, MA). Film was scanned using a
CanoScan LIDE 80 scanner (Canon, Lake Success, NY) and band
densitometry was measured using AlphaEaseFC software, version
3.1.2 (Alpha Innotech/Cell Biosciences, Santa Clara, CA). For co-
IP, the protein complexes were immunoprecipitated from 125 mg
total lysate protein with 20 mL Protein A/G-Sepharose beads and
2 mg anti-Nrf1 antibody. The immunoprecipitated complexes
were subjected immunobloting using anti-ubiquitin antibody.
Electrophoretic Mobility-Shift Assay (EMSA)
Cells were lysed as described above and 20 mg total protein was
reacted with a biotinylated dsDNA EpRE probe of the human
glutamate-cysteine ligase, modifier subunit (gclm) promoter [44]
and was subjected to non-denaturing electrophoresis according to
the manufacturer’s instructions (Panomics, Fremont, CA). Protein-
DNA complexes were transferred onto an Amersham Hybond-N
+
membrane (GE Healthcare, Buckinghamshire, UK) and visualized
using streptavidin-HRP and chemiluminescence as described
above for Western blots.
Bioinformatic Analyses
ClustalW tool [45] was used for multiple amino acid alignment
http://www.ebi.ac.uk/Tools/clustalw2/index.html). Nrf1 PEST
domain was identified using PESTfind algorythm that was pre-
viously located at https://emb1.bcc.univie.ac.at/toolbox/pestfind/
pestfind-analysis-webtool.htm. The prediction of phosphorylation
sites was performed using NetPhos 2.0 server available at http://
www.cbs.dtu.dk/services/NetPhos/[46]. The prediction of kinase-
specific phorphorylationsites[47]was performed with http://www.
cbs.dtu.dk/services/NetPhosK/.
Statistical Analyses
Data are presented as means 6 SEM of at least three
independent experiments. The results were considered statistically
significant at p,0.05 for the Student’s paired t-test.
Supporting Information
Figure S1 Oxidative stressor AAPH induces Nrf1 DNA binding
and stabilizes p95 Nrf1 form independently of p120. (A) The Nrf1-
specific band on an EMSA format was determined by including
20 mg of the COS7 cell lysate with: 1) no antibody; 2) anti-actin
antibody; 3) anti-Nrf1 antibody; 4) anti-Nrf1 antibody, no lysate;
and 5) neither lysate nor antibody (probe only). The experiment
was performed twice with the same outcome. (B) COS7 cells were
treated with 80 mM AAPH for 6 hours [48,49] and the lysates
were subjected to EMSA and Western blotting (C). The position of
AAPH-inducible Nrf1 semi-specific bands is shown with arrows in
A and B.I nC, both short- and long-time exposure of bands are
shown for better clarity.
(TIF)
Figure S2 Oxidative stressors AAPH and tBHQ, hypoxia and
CHX destabilize the p250 form of Nrf1. COS7 cells were treated
for six hours with (A) 80 mM AAPH, 100 (+) or 200 (++) mM tBHP
or hypoxia for twenty-four hours or with (B) 100 mg/mL CHX
[50] for the times indicated, after which cells were harvested and
total cell lysates were subjected to immunoblotting with anti-Nrf1
or anti-b-tubulin antibodies. Molecular masses are indicated in
kDa. The results of two independent experiments (A)o ra
representative result of three independent experiments (B) are
shown. Nrf1 forms (p65, p95 and p250) are indicated with arrows.
(TIF)
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